Xencor, Inc. $XNCR Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 47.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,566 shares of the biopharmaceutical company’s stock after selling 60,779 shares during the quarter. SG Americas Securities LLC’s holdings in Xencor were worth $815,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. BVF Inc. IL lifted its position in shares of Xencor by 160.3% during the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after purchasing an additional 4,393,579 shares during the last quarter. Legal & General Group Plc increased its holdings in Xencor by 603.7% in the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after buying an additional 1,092,095 shares during the last quarter. State Street Corp raised its stake in Xencor by 22.7% in the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after buying an additional 833,423 shares in the last quarter. Jefferies Financial Group Inc. raised its stake in Xencor by 620.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after buying an additional 620,440 shares in the last quarter. Finally, RTW Investments LP lifted its holdings in Xencor by 8.9% during the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after buying an additional 556,407 shares during the last quarter.

Xencor Price Performance

Shares of XNCR stock opened at $15.00 on Monday. The stock has a market capitalization of $1.11 billion, a PE ratio of -6.55 and a beta of 0.86. Xencor, Inc. has a 52-week low of $6.92 and a 52-week high of $18.69. The stock’s 50-day moving average price is $12.59 and its 200 day moving average price is $12.77.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The company had revenue of $4.52 million for the quarter, compared to analyst estimates of $27.86 million. During the same period in the previous year, the business posted ($0.66) earnings per share. The firm’s revenue was down 86.2% compared to the same quarter last year. Analysts expect that Xencor, Inc. will post -3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on XNCR shares. Zacks Research lowered Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. raised their price objective on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $24.50.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.